This Plain Language Summary of Publication article (PLSP) from Future Cardiology outlines the SEQUOIA-HCM study that tested aficamten against placebo in obstructive hypertrophic cardiomyopathy (oHCM) patients. The study included 282 participants (142 receiving aficamten, 140 receiving placebo) over 24 weeks. Aficamten reduces overactive myosin protein activity that causes excessive heart muscle contraction and obstruction of blood flow in oHCM. Researchers evaluated treatment effectiveness through exercise tests, quality of life surveys, symptom assessments, cardiac function measurements, and side effect monitoring.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy’ and was published in The New England Journal of Medicine. 

Visit NEJM using the link to read the original article.